1
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, April 7, 1998: US05736137 (387 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


2
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, July 7, 1998: US05776456 (187 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


3
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Burns Doane Swecker & Mathis, December 1, 1998: US05843439 (100 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


4
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma. IDEC Pharmaceutical Corporation, Robin L Teskin, June 4, 2002: US06399061 (86 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


5
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Anti-CD20 antibodies. Biogen Idec, Sidley Austin, September 9, 2008: US07422739 (83 worldwide citation)

Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.


6
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Robin L Teskin, Pillsbury Winthrop, January 27, 2004: US06682734 (35 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


7
Syamal Raychaudhuri, William H Rastetter: Induction of cytotoxic T-lymphocyte responses. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, August 7, 2001: US06270769 (25 worldwide citation)

Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consis ...


8
Syamal Raychaudhuri, William H Rastetter: Induction of cytotoxic T-lymphocyte responses. IDEC Pharmaceutical Corporation, Burns Doane Swecker & Mathis, December 17, 1996: US05585103 (24 worldwide citation)

Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consis ...


9
David A Estell, Robert A Lazarus, David R Light, Jeffrey V Miller, William H Rastetter: Ascorbic acid intermediates and process enzymes. Genentech, July 12, 1988: US04757012 (22 worldwide citation)

Recombinant plasmids containing the gene encoding 2,5-diketogluconic acid reductase are prepared and used to transform microorganisms. 2,5,DKG reductase is expressed by the microorganisms.


10
Stephen Anderson, David R Light, Cara Marks, William H Rastetter: Ascorbic acid intermediates and process enzymes. Genentech, Ginger R Dreger, April 16, 1991: US05008193 (21 worldwide citation)

Methods for producing ascorbic acid using recombinant means comprising the transfer of genetic material by conjugation, a host cell lacking, entirely or to such an extent as not to be commercially useful, one or more enzymes in the metabolic path converting glucose to 2 keto-L-gulonic acid.